Medication Effect Tool

For clinical and educational use only. Not intended to replace professional medical judgment.

Limitations and Assumptions:

  1. Population Heterogeneity: Data derived primarily from clinical trial populations may not fully represent real-world responses.

  2. Baseline LDL-C Variability: Combination effects assume moderate baseline LDL-C levels (130-160 mg/dL).

  3. Adherence: Estimates assume perfect medication adherence.

  4. Time to Effect: Statin and ezetimibe effects at 6-8 weeks; PCSK9 inhibitors at 12 weeks; inclisiran at 6 months (after loading)

  5. Drug Interactions: No adjustment made for potential drug-drug interactions

  6. Genetic Factors: No stratification by genetic polymorphisms (e.g., PCSK9, SLCO1B1)

Note: This comprehensive table represents the best available evidence synthesized from clinical trials, meta-analyses, FDA-approved labeling, and expert guidelines. For triple combinations and some dual combinations with limited direct evidence, estimates are modeled based on established pharmacodynamic principles and known mechanisms of action. Clinical decision-making should account for individual patient characteristics, baseline lipid levels, cardiovascular risk, and treatment goals.